Abstract
BackgroundThe local Pharmacy and Therapeutics Committee (PTC) approved Teriflunomide (TE) and Dimethylfumarate (DMF) for the treatment of relapsing-remitting multiple sclerosis (RRMS). These drugs were used in first-line treatment in adults...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have